Desmopressin as a Therapy for Nocturnal Enuresis in Pediatric Patients With Sickle Cell Disease

About the study

This study assesses if using the medication desmopressin will decrease nightime bedwetting in
children with sickle cell disease.

Study point of contact

Deepa Manwani, MD
718-741-2342
dmanwani@montefiore.org
Kerry Morrone, MD
718-741-2342
kmorrone@montefiore.org

Locations

1 United States site

Age

8 to 21 Years

Genotypes

Hemoglobin SS

Phase

Phase 4

Study type

Interventional

Gender

All

Interventions

Drug

Compensation

Unknown

participation requirements

1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal

2. Patients with at least two episodes of primary nocturnal enuresis per week or four
episodes over the two weeks prior to enrollment.

3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric
urologist as not having other etiologies of enuresis (e.g. overactive detrusor
activity, a genitourinary anatomic abnormality)

participation restrictions

1. Patients with developmental delay or neurologic dysfunction secondary to stroke.

2. Patients with hypertension or underlying renal disease.

3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing
normal genitourinary anatomy is sufficient to clear a patient for the study.

4. Patients with daytime urinary incontinence

5. Patients with glucosuria on urinalysis.

6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric
urologist to rule out other etiologies of enuresis.

7. Patients who are pregnant.

8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

Locations

  • Bronx, New York, United States, Children's Hospital at Montefiore, 10467 [Recruiting]
Last updated 2021-08-06